Zacks.com on MSN4d
MRK's sNDA for Welireg in Rare Tumors Gets FDA's Priority TagThe FDA accepts and grants priority review to Merck's sNDA for Welireg to treat advanced pheochromocytoma and paraganglioma.
The Securities Commission of The Bahamas (SCB) has assessed $221.55 million in regulatory penalties against FTX Digital ...
$221.55 million regulatory claim against FTX DM. The Court-approved “Claim Subordination Agreement” between the JOLs and the Commission enables the reprioritisation of the payment of all ...
Alnylam Pharmaceuticals , Inc. (NASDAQ:ALNY), a leader in RNA interference (RNAi) therapeutics, stands at a pivotal juncture as it seeks to capitalize on the burgeoning market for ...
Biogen Inc. announced that the U.S. Food and Drug Administration (FDA) has accepted the company's supplemental New Drug Application (sNDA) and the European Medicines Agency (EMA) has validated the ...
$221.55 million regulatory claim against FTX DM. The Court-approved “Claim Subordination Agreement” between the JOLs and the Commission enables the reprioritisation of the payment of all ...
In a good-news-bad-news week for Biogen, the company will cut an undisclosed number of employees, just as a higher dose of ...
Exelixis, Inc. (Nasdaq: EXEL) today announced results from a subgroup analysis of the phase 3 CABINET pivotal study of ...
# The Supreme Court yesterday approved the Securities Commission’s bid to relegate its $221.55m claim against FTX behind those of the insolvent crypto exchange’s clients and other victims.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback